• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

NextFlex, Profusa Unveils Injectable Biosensor for Continuous Oxygen Monitoring in Tissue

by Jasmine Pennic 02/18/2019 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

NextFlex, Profusa Unveils Injectable Biosensor for Continuous Oxygen Monitoring in Tissue

Today at FLEX 2019, integrated biosensor makers Profusa and NextFlex unveiled a skin-worn reader prototype with an injected hydrogel biosensor for continuous oxygen monitoring in tissue. The Lumee™ Oxygen Platform is intended for use in patients with potential acute and/or chronic changes in tissue oxygen levels who may benefit from continuous monitoring.

Lumee Oxygen Hydrogel Biosensor

 The Lumee Oxygen Hydrogel biosensor, a tiny flexible fiber (3 mm to 5 mm long and approximately 500 microns in diameter) that is placed under the skin with a specially designed injector. The Lumee optical reader measures oxygen levels in the surrounding tissue by exciting the biosensor with light and then measuring the emitted fluorescent light. Profusa’s biosensors fully integrate with the body’s tissue without any metal devices or electronics, avoiding the foreign body response for up to two years. The injectable hydrogel sensor is currently CE Marked in Europe and it is not yet commercially available elsewhere.

Skin-Worn Reader Prototype Details

The skin-worn reader was developed in record time, just in four months, at NextFlex’s research center and fab in San Jose, Calif., since the facility and the team combine expertise in flexible hybrid electronics, engineering, materials science and optics all reside under one roof. NextFlex has taken Profusa’s design work and criteria and pushed them toward a smaller, flexible reality that works in harmony with Profusa’s tissue sensors. With this stage completed and other medical devices in the pipeline, NextFlex is engaged in the application for FDA approval for medical device manufacturing.

“Ten years ago, you couldn’t build a reader that could sense multiple signals and filter out the ‘noise’ of the body’s other signals, all while being small and skin-worn,” said Ben Hwang, CEO of Profusa. “With the latest advancements in flexible hybrid electronics technology, it’s just mature enough to work the way we want — primarily because we selected the right domain expertise partner to work with, namely NextFlex. Rather than managing development across multiple R&D and manufacturing facilities, we found a single place at NextFlex’s Technology Hub, where we could develop our solution in very short time and have the right conversations to move our reader design toward production at scale.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Biosensors, continuous oxygen monitoring, Continuous Vital Sign Monitoring

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Digital Health Funding Q3 2025: Choppy Undercurrents Beneath a Steady Surface

Featured Interview

ConcertAI VP Shares View on AI Hallucinations and the Fabricated Data Crisis in Scientific Publishing

Most-Read

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

KLAS Report: Epic's Native Ambient Speech Tool Reshapes Customer AI Strategies

KLAS Report: Epic’s Native Ambient Speech Tool Reshapes Customer AI Strategies

Epic Unveils MyChart Central and New APIs to Advance Interoperability at Open@Epic

Epic Outlines Roadmap for Next-Generation Data Sharing at Open@Epic

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Oracle Confirms Layoffs in Kansas City

Oracle Confirms Layoffs in Kansas City

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Optain Health Secures $26M to Advance AI-Powered Retinal Screening

Optain Health Secures $26M for AI-Powered Retinal Screening

Sutter Health and Epic Launch "Sutter Sync" to Optimize Remote Chronic Care

Sutter Health and Epic Launch “Sutter Sync” to Optimize Remote Chronic Care

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |